Scancell Share Discussion Threads

[888icb] 16/2/2021 17:26

Good progress today closing on the Uncrossing trade at 24p Up 14.2% on volume of 12 million. The continuing press coverage is getting Scancell noticed globally and investors are realising the potential for the company to be rerate to a much higher value. Exciting times particularly as it can help to get everyone’s life COVID free for ever.

[bermudashorts] 16/2/2021 17:08

The best thing about the FT article today was the fact that it was tweeted out by CEPI. For those who aren't aware of CEPI, it's the Coalition for Epidemic Preparedness Innovations launched in Davos in 2017 and well worth a google. The fact they've tweeted the FT article is great exposure for Scancell.

[inanaco] 16/2/2021 17:06

its not a Lock and key ..... its a takeover which creates a new bonding point allowing the virus inside the cell


"""Recently, the high-resolution cryo-electron microscopy structure obtained on the full-length human ACE2 in the presence of the RBD of the S glycoprotein of SARS-CoV-2 suggests simultaneous binding of two S-glycoprotein trimers to an ACE2 dimer3. The S2 subunit is further cleaved by host proteases located immediately upstream of the fusion peptide6, leading to the activation of the glycoprotein that undergoes extensive irreversible conformational changes facilitating the membrane fusion process. Altogether, the information obtained so far highlights the fact that CoV entry into susceptible cells is a complex process that requires the concerted action of receptor binding and proteolytic activation of the S glycoprotein at the host cell surface to finally promote virus–cell membrane fusion."""

[dominiccummings] 16/2/2021 16:58

The principle is what I am getting at. The spike protein can't change or the virus won't be able to enter cells and replicate.

[inanaco] 16/2/2021 16:27

its a fusion process not exactly a key, once engaged the elements fuse in a non reversible fashion

[dominiccummings] 16/2/2021 16:05

Surely, variants cannot alter the spike protein as it is the key that opens access to the cell.

[j777j] 16/2/2021 16:01

Ft this pmThe clean exit from the coronavirus pandemic promised by Covid-19 vaccines has been sullied by the arrival of new variants. Some of these viral newcomers appear to be putting up a fight against the current crop of jabs.The scramble to update vaccines that have barely been rolled out is now pushing some towards a more ambitious goal: universal "variant-proof" vaccines, able to fend off different varieties of the same virus family."Such pan-virus vaccines could be made in advance and deployed before the next emerging infection becomes a pandemic," wrote Dennis Burton and Eric Topol from the Scripps Research institute in a Nature commentary last week. "We call for an investment now in basic research leading to the stockpiling of broadly effective vaccines?.?.?.?Surely, global governments that together spend $2tn a year on defence can find a few hundred million dollars to stop the next pandemic?"Many variants of Sars-Cov-2, the virus that causes Covid-19, behave no differently from their progenitors. A handful, though, appear able to partially resist the immunity conferred by vaccines. The Oxford/AstraZeneca jab is less effective against the dominant coronavirus variant in South Africa than against the variant circulating in the UK, in terms of preventing mild to moderate disease (though, importantly, it is still believed to protect against severe disease and death). The South African government has halted its rollout.An unreviewed preprint suggests mRNA vaccines, like those from Pfizer and Moderna, might also see their potency dented by the mutations first detected in South Africa and Brazil.The apparent drop in vaccine efficacy has arisen because Covid-19 vaccines are mostly designed to produce antibodies that bind to the virus "spike" protein, which latches on to human cells to infect them. If mutations alter the spike protein sufficiently, antibodies can no longer "catch" the viral invader as effectively. These mutated viruses are less easily cleared from the body - and gain a survival advantage.Now, the vision is to harness more generalised responders, known as broadly neutralising antibodies. These types of antibodies have been isolated from Covid-19 patients and found to also neutralise Sars-Cov-1, another virus in the coronavirus family responsible for severe acute respiratory syndrome, or Sars. If they can quash several distinct coronaviruses, then they might also be able to combat current and future variants of the pandemic virus.The challenge comes in finding a jab that produces these versatile antibodies. One starting point is to identify which parts of the virus remain unchanged as it mutates and then designing vaccines on the basis of these stable regions.Researchers at the University of Nottingham in the UK are adopting this approach. While current vaccines target the S (spike) protein, they are gunning for both the S protein and the nucleocapsid, or N, protein. The latter helps the virus to replicate and mutates more slowly than the spike protein. The scientists have teamed up with the company Scancell and Nottingham Trent University for a phase 1 clinical trial of its vaccine candidate, SN14.The current jabs might also offer clues, according to Deborah Dunn-Walters, professor of immunology at the University of Surrey and chair of a Covid-19 task force. "We will eventually have lots of different vaccines and some might be more tolerant of variants than others," she says. Those, she suggests, could be iterations along the road to a universal vaccine.Alternatively, future Covid-19 vaccines could contain components targeting several variants, much as the seasonal flu jab features the three or four strains forecast to pose the biggest health risks. The success of flu jabs depends on how well predictions match reality: between 2009 and 2019, their effectiveness hovered roughly between 20 and 60 per cent. Those underwhelming numbers, plus the pandemic potential of influenza, have spurred concerted efforts to develop a universal flu jab - without success. Two candidates flopped in clinical trials last year.The search should continue. Flu is a notorious viral shape-shifter, more so than the virus that causes Covid-19. There have been three post-1918 flu pandemics: in 1957, 1968 and 2009. As the light at the end of Covid-19 tunnel brightens, we should not discount other surprises coming down the track

[emptyend] 16/2/2021 15:34

TF, Your problem with links is likely due to a desktop. I use ipad and an Andoid phone - both are perfect.Re the FT I don't have a sub but that link opened fully. There is a low limit for free FT articles (2 a month or something, I think).More importantly, the whole tone of recent press coverage has been aimed at universal vaccines and the increasing recognition that broader vaccine coverage is required. That being the case, Scancell certainly isn't the only player but, in a UK context, it is a pretty relevant one. Lets hope it gets the backing that is needed.....if the government has any interest at all in taking out some insurance against variants circumventing existing vaccines, then surely the Covidity programme should get backing by one means or another!?

[torquayfan] 16/2/2021 15:09

Banshee that links - but doesn't go behind the paywall. If you have the sub you get it if you don't, you don't. But in the post I referred to on LSE earlier, you get in without the sub. But I could be wrong.

I think if you have the sub and you post the link, it works for you but no-one subless! Enough - I tried and GNA

[banshee] 16/2/2021 15:02

In the FT today (may need sub)

A universal Covid vaccine may be our best means of escape



Extract

"The challenge comes in finding a jab that produces these versatile antibodies. One starting point is to identify which parts of the virus remain unchanged as it mutates and then designing vaccines on the basis of these stable regions.

Researchers at the University of Nottingham in the UK are adopting this approach. While current vaccines target the S (spike) protein, they are gunning for both the S protein and the nucleocapsid, or N, protein. The latter helps the virus to replicate and mutates more slowly than the spike protein. The scientists have teamed up with the company Scancell and Nottingham Trent University for a phase 1 clinical trial of its vaccine candidate, SN14."

[mcrudden] 16/2/2021 15:00

To be honest i use it through an app mostly on an iPad or phone so maybe it's desktop that requires it.

[torquayfan] 16/2/2021 14:42

EE - Windows 10 outdated ? I even turned my VPN off.
A connecting link surely get's underlined ?
No idea - I can't get in, then change H or TT then it underlines and gives access.
Never mind.

[mcrudden] 16/2/2021 14:00

Yes I get that a lot when I post links as well ... people want the h made into a H but every link works perfectly for me both ways

[emptyend] 16/2/2021 13:34

The links work perfectly. There is no need to keep reposting them!!One or two people may have outdated software, but most don't...

[albert arthur] 16/2/2021 13:16

Are you using desktop or mobile? It's working on mobile for me. Shared the Tweet.https://twitter.com/albert__arthur/status/1361664181095845889?s=21

[torquayfan] 16/2/2021 13:10

AA - thanks but does the link work ? ATB

[albert arthur] 16/2/2021 13:08

Fresh enough, I posted 37 mins ago.

[torquayfan] 16/2/2021 13:01

Crumbs link 11.17 on LSE gets you into the FT article - hopefully.

But not here.

[emptyend] 16/2/2021 12:57

...published only two hours ago, I note....

[albert arthur] 16/2/2021 12:30

FT fresh article:https://www.google.co.uk/amp/s/amp.ft.com/content/c6d663e1-9753-4a92-8d7c-599fd0dd45c7

[emptyend] 16/2/2021 11:12

Re Covid vaccine trials, this is part of an email sent by NIHR today to the 441,000 people who have signed up for trials in the UK:QUOTEthank you to everyone who has responded to their invitation email from the registry to take part in a study. The UK has been extremely busy running multiple COVID-19 vaccine studies. In the space of just two months, 15,203 people were recruited into the Novavax phase III study, the largest double blind placebo controlled vaccine study ever to take place in the UK. The result: the vaccine was found to be 89.3% effective at preventing COVID-19. In another world first, in January, 153 participants were recruited into the Valneva Phase I/II study in less than a month. 5,769 participants have been enrolled into the Janssen two dose phase III study (ENSEMBLE-2), while 864 participants are taking part in the Astrazeneca monoclonal antibody study, with both studies still recruiting.However, as you can see, the fight against COVID-19 is far from over and there are many questions yet to answer. There are ongoing studies which still need volunteers - not only the innovative study pipeline of new vaccines, but also studies which will help inform policy. One such study recently launched is looking at the effectiveness of alternating doses of approved vaccines. Funded by the Vaccine Taskforce, it is also looking at different time intervals between the doses. These studies will generate critical safety and effectiveness data which will drive informed policy making decisions. You can play your role here. Step up. Please respond to your invitation when it arrives in your inbox.UNQUOTE

[emptyend] 16/2/2021 10:02

J777J,On the contrary. The model of deals...and the reasons for them, is highly similar. More particularly, Scancell don't need "cash" per se.....they need "work". Delivering the "work" will be required for developing the Covidity project - so a manufacturer will (one expects) finance phase 3 to earn a stake in the Covidity project. BUT neither party needs to do a deal involving Scancell equity.In 2023, however, the project portfolio will have moved on more broadly - and at that stage a major pharma may take a stake (probably from Redmile/Vulpes)....

[ny boy] 16/2/2021 09:46

Aye, strong hold here

(TRX) is probably the one with the most exciting potential, just starting a move again dyor as usual

[888icb] 16/2/2021 09:29

Currently Up 12% on volume of 4 million so steady progress as we await news.

[j777j] 16/2/2021 09:28

The licensing route also possible.


With all the PR it will have put Scancell's other potentially world beating products into the headlights and who knows what outcome that could lead to?

Reminds me of that Monty Python sketch with the fat man and the mint

"I'll take the lot."